Shares of clinical stage biotechnology company Longeveron Inc. (LGVN) are rising more than 20% Tuesday morning at $3.89.
Longeveron today reported long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS).
The data showed that 100% of the 10 patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-BTM during their Stage 2 surgery.
LGVN has traded in the range of $2.50 – 9.34 in the last 1 year.
Source: Read Full Article
Lates News:
-
Bitcoin ($BTC) Investors Should Be ‘Accumulating’ Before Rise to $150,000: Bloomberg Analyst
-
Binance Secures First Full Crypto Exchange Licenses in El Salvador
-
Ancient Bitcoin Whale Comes Back to Life, Moves $38 Million After Making 13,500% Gain
-
Bitcoin Heads Towards $30,000 As It Hits New Peak Despite Ongoing Market Woes
-
Facebook’s Former Head of Crypto Manages To Bash Ethereum Without Meaning To Do So